Cytotoxic T lymphocyte antigen 4 (CTLA-4) is a key negative immunoregulatory molecule with characteristics of gene polymorphisms. Genetically predisposed CTLA-4 alteration in humans was associated with gastric cancer (GC) development. To explore the association of CTLA-4 polymorphism with susceptibility of noncardiac GC (NCGC), 490 NCGC patients and 1476 control individuals were studied. Four CTLA-4 polymorphisms were genotyped with SNPscan genotyping assays and the haplotypes were constructed with SHESIS software. Frequencies of the CTLA-4 haplotypes were estimated using an expectation–maximization algorithm. The CTLA-4 polymorphism genotype distribution and allele frequencies were not significantly different between the NCGC patients and the control subjects. The CTLA-4 haplotypes did not exhibit a significantly increased risk for NCGC patients. Adjusting status of age, sex, smoking status, alcohol use, and body mass index could not moderate any of the relationships. Data suggested that CTLA-4 polymorphisms (rs3087243, rs16840252, rs733618, and rs231775) were not significantly associated with the risk of NCGC in this Chinese population studied.
Get full access to this article
View all access options for this article.
References
1.
AlegreM.L., FrauwirthK.A., and ThompsonC.B. (2001). T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol, 1, 220–228.
2.
ApplemanL., BerezovskayaA., GrassI., and BoussiotisV. (2000). CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol, 164, 144–151.
3.
BrayF., FerlayJ., SoerjomataramI., SiegelR.L., TorreL.A., and JemalA. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394–424.
4.
Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 513, 202–209.
5.
ChenS., WangY., ChenY., LinJ., LiuC., KangM., et al. (2017). Investigation of cytotoxic T-lymphocyte antigen-4 polymorphisms in non-small cell lung cancer: a case-control study. Oncotarget, 8, 76634–76643.
6.
ChenW., ZhengR., BaadeP.D., ZhangS., ZengH., BrayF., et al. (2016). Cancer statistics in China, 2015. CA Cancer J Clin, 66, 115–132.
7.
ColquhounA., ArnoldM., FerlayJ., GoodmanK.J., FormanD., and SoerjomataramI. (2015). Global patterns of cardia and non-cardiac gastric cancer incidence in 2012. Gut, 64, 1881.
8.
CozarJ.M., RomeroJ.M., AptsiauriN., VazquezF., VilchezJ.R., TalladaM., et al. (2007). High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol, 68, 698–704.
9.
de JongV.M., ZaldumbideA., ArV.D.S., LabanS., KoelemanB.P., and RoepB.O. (2016). Variation in the CTLA4 3'UTR has phenotypic consequences for autoreactive T cells and associates with genetic risk for type 1 diabetes. Gene Immun, 17, 75–78.
10.
de MartelC., FormanD., and PlummerM. (2013). Gastric cancer: epidemiology and risk factors. Gastroenterol Clin N Am, 42, 219–240.
11.
EtoK., OhyamaS., YamaguchiT., WadaT., SuzukiY., MitsumoriN., et al. (2006). Familial clustering in subgroups of gastric cancer stratified by histology, age group and location. Eur J Surg Oncol, 32, 743–748.
12.
FangM., HuangW., MoD., ZhaoW., and HuangR. (2018). Association of five snps in cytotoxic t-lymphocyte antigen 4 and cancer susceptibility: evidence from 67 studies. Cell Physiol Biochem, 47, 414–427.
13.
FangW., ZhangZ., ZhangJ., CaiZ., ZengH., ChenM., et al. (2015). Association of the CTLA4 gene CT60/rs3087243 single-nucleotide polymorphisms with Graves' disease. Biomed Rep, 3, 691.
14.
FerlayJ., ShinH.R., BrayF., FormanD., MathersC., and ParkinD.M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893–2917.
15.
HadiniaA., HossieniS.V., ErfaniN., Saberi-FiroziM., FattahiM.J., and GhaderiA. (2010). CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. J Gastroenterol Hepatol, 22, 2283–2287.
16.
HartgrinkH.H., JansenE.P., van GriekenN.C., and van de VeldeC.J. (2009). Gastric cancer. Lancet, 374, 477–490.
17.
HemminkiK., SundquistJ., and JiJ. (2007). Familial risk for gastric carcinoma: an updated study from Sweden. Br J Cancer, 96, 1272.
18.
HowsonC.P., HiyamaT., and WynderE.L. (1986). The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev, 8, 1–27.
19.
HuL., LiuJ., ChenX., ZhangY., LiuL., ZhuJ., et al. (2010). CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infection-related cancers-hepatocellular carcinoma and cervical cancer. Hum Immunol, 71, 888–891.
20.
IdrisZ.M., MiswanN., MuhiJ., MohdT.A.A., KunJ.F.J., and NoordinR. (2011). Association of CTLA4 gene polymorphisms with lymphatic filariasis in an East Malaysian population. Hum Immunol, 72, 607–612.
21.
JafariM., and GhaneiM. (2010). CTLA-4 in autoimmune diseases—a general susceptibility gene to autoimmunity?. Clin Toxicol, 48, 184–192.
22.
JonesG., WuS., JangN., FulcherD., HoganP., and StewartG. (2010) Polymorphisms within the CTLA4 gene are associated with infant atopic dermatitis. Br J Dermatol, 154, 467–471.
23.
JorgeR.T., DianaG.M., and JorgeA.V. (2013). CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev, 12, 1171–1176.
24.
LingV., WuP.W., FinnertyH.F., SharpeA.H., GrayG.S., and CollinsM. (1999). Complete sequence determination of the mouse and human CTLA4 gene loci: cross-species DNA sequence similarity beyond exon borders. Genomics, 60, 341–355.
25.
ParkinD., BrayF., FerlayJ., and PisaniP. (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74.
26.
PawlakE., KarabonL., WlodarskapolinskaI., JedynakA., JonkiszA., TomkiewiczA., et al. (2010). Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population. Hum Immunol, 71, 195–200.
27.
RuanK., FangX., and OuyangG. (2009). MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett, 285, 116–126.
28.
ScheipersP., and ReiserH. (1998). Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking. Proc Natl Acad Sci U S A, 95, 10083–10088.
29.
SharpeA.H., and FreemanG.J. (2002). The B7–CD28 superfamily. Nat Rev Immunol, 2, 116–126.
30.
SunT., ZhouY., YangM., HuZ., TanW., HanX., et al. (2008). Functional genetic variations in cytotoxic t-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res, 68, 7025.
31.
TangW., WangY., ChenS., LinJ., ChenB., YuS., et al. (2016). Investigation of cytotoxic T-lymphocyte antigen 4 (CTLA4) polymorphisms in gastric cardia adenocarcinoma. Scand J Immunol, 83, 212–218.
32.
TeftW.A., KirchhofM.G., and MadrenasJ. (2006). A molecular perspective of CTLA-4 function. Annu Rev Immunol, 24, 65–97.
33.
TivolE.A., BorrielloF., SchweitzerA.N., LynchW.P., BluestoneJ.A., and SharpeA.H. (1995). Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 3, 541–547.
34.
TivolE.A., SchweitzerA.N., and SharpeA.H. (1996). Costimulation and autoimmunity. Curr Opin Immunol, 8, 822–830.
35.
UedaH., HowsonJ.M., EspositoL., HewardJ., SnookH., ChamberlainG., et al. (2003). Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature, 423, 506–511.
36.
WalunasT.L., LenschowD.J., BakkerC.Y., LinsleyP.S., FreemanG.J., GreenJ.M., et al. (1994). CTLA-4 can function as a negative regulator of T cell activation. Immunity, 1, 405–413.
37.
WangY., WangX., and ZhaoR. (2015). The association of CTLA-4 A49G polymorphism with colorectal cancer risk in a Chinese Han population. Int J Immunogenet, 42, 93–99.
38.
YinJ., WangL., ShiY., ShaoA., TangW., WangX., et al. (2014). Interleukin 17A rs4711998 A>G polymorphism was associated with a decreased risk of esophageal cancer in a Chinese population. Dis Esophagus, 27, 87–92.
39.
YongY., and LinH.E. (2005). SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res, 15, 97.
40.
ZhengL., YinJ., WangL., WangX., ShiY., ShaoA., et al. (2013). Interleukin 1B rs16944 G>A polymorphism was associated with a decreased risk of esophageal cancer in a Chinese population. Clin Biochem, 46, 1469–1473.
41.
ZouC., QiuH., TangW., WangY., LanB., and ChenY. (2018). CTLA4 tagging polymorphisms and risk of colorectal cancer: a case-control study involving 2,306 subjects. Onco Targets Ther, 11, 4609.
